

# Jacobus R B J Brouwers

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6007106/publications.pdf>

Version: 2024-02-01

13  
papers

472  
citations

1163117

8  
h-index

1125743

13  
g-index

13  
all docs

13  
docs citations

13  
times ranked

667  
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug-Related Problems in Hospitalised Patients. <i>Drug Safety</i> , 2000, 22, 321-333.	3.2	155
2	Chlorpromazine Equivalents Versus Defined Daily Doses: How to Compare Antipsychotic Drug Doses?. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 657-659.	1.4	104
3	Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options. <i>Clinical Pharmacokinetics</i> , 2017, 56, 683-688.	3.5	59
4	Cost-Benefit Analysis of the Detection of Prescribing Errors by Hospital Pharmacy Staff. <i>Drug Safety</i> , 2002, 25, 135-143.	3.2	53
5	Pharmacogenetics as a tool in the therapy of schizophrenia. <i>International Journal of Clinical Pharmacy</i> , 2005, 27, 20-30.	1.4	36
6	Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations. <i>SAGE Open Medicine</i> , 2016, 4, 205031211664367.	1.8	14
7	A Novel Ileocolonic Release Peppermint Oil Capsule for Treatment of Irritable Bowel Syndrome: A Phase I Study in Healthy Volunteers. <i>Advances in Therapy</i> , 2018, 35, 1965-1978.	2.9	12
8	No involvement of the adenosine A2A receptor in tardive dyskinesia in Russian psychiatric inpatients from Siberia. <i>Human Psychopharmacology</i> , 2012, 27, 334-337.	1.5	11
9	Dehydroepiandrosterone sulphate as a putative protective factor against tardive dyskinesia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 50, 172-177.	4.8	9
10	Prescribing of sulfasalazine, azathioprine and methotrexate round pregnancy—a descriptive study. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 52-61.	1.9	8
11	Combined use of NSAIDs and SSRIs increases the risk for gastrointestinal adverse effects. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 119-119.	2.4	4
12	Biosimilars of low molecular weight heparins: Relevant background information for your drug formulary. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2479-2486.	2.4	4
13	Pharmacoeconomics of <i>Helicobacter pylori</i> : eradication versus maintenance therapy in controlling peptic ulcer disease. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2001, 1, 19-24.	1.4	3